Clomipramine: Overview
Clomipramine is a tricyclic antidepressant (TCA) that functions as a non-selective serotonin reuptake inhibitor (SRI), historically the first medication proven effective for obsessive-compulsive disorder (OCD), though now considered second-line to SSRIs due to its less favorable tolerability profile. 1
Mechanism of Action
- Primary mechanism: Potent inhibition of serotonin (5-HT) reuptake at the neuronal level 2, 3
- Secondary effects: Its active metabolite, desmethylclomipramine, is a potent norepinephrine reuptake inhibitor 2, 3
- The actual neurochemical mechanism underlying its therapeutic effects remains unknown, but serotonergic modulation is considered central to its efficacy in OCD 2
Clinical Indications
Primary Indication: Obsessive-Compulsive Disorder
- FDA-approved specifically for OCD treatment 2
- Clomipramine was the first agent to demonstrate efficacy in OCD 1
- Meta-analyses suggest clomipramine may be more efficacious than SSRIs, though this finding is debated because clomipramine trials were conducted earlier on less treatment-resistant patients 1
- Head-to-head trials comparing clomipramine with SSRIs show equivalent efficacy 1
- Current positioning: SSRIs are first-line agents due to superior safety and tolerability profiles, making them more suitable for long-term treatment 1
Use in Treatment-Resistant OCD
- Clomipramine serves as an augmentation strategy for SSRI-resistant OCD 1
- In the only double-blind RCT comparing pharmacological strategies in SSRI-resistant OCD, fluoxetine plus clomipramine significantly reduced OCD severity and was superior to fluoxetine plus quetiapine 1
- Critical safety concern: Combining clomipramine with SSRIs increases blood levels of both drugs, raising risk of severe and potentially life-threatening events including seizures, cardiac arrhythmias, and serotonergic syndrome 1
Other Psychiatric Uses
- Depression: Particularly treatment-resistant depression 4
- Panic disorder: Reduces frequency and severity of panic attacks within 7-21 days, with efficacy maintained for at least 12 months 4
- Premature ejaculation: Doses of 25-50 mg/day or 25 mg taken 4-24 hours prior to intercourse have shown efficacy 5
Pharmacokinetics
- Bioavailability: Extensive first-pass metabolism reduces oral bioavailability to less than 62% 2, 3
- Peak plasma concentrations: Occur 2-6 hours (mean 4.7 hours) after oral administration 2
- Distribution: Volume of distribution 9-25 L/kg; 97% protein-bound (primarily to albumin) 2, 3
- Metabolism: Extensively biotransformed to desmethylclomipramine and other metabolites via glucuronide conjugation 2
- Elimination half-life: 20-24 hours for clomipramine; mean 39 hours when including metabolites 3, 6
- Excretion: 66% in urine, remainder in feces via biliary elimination 2, 6
Important Pharmacokinetic Considerations
- Non-linear kinetics: Steady-state plasma concentrations and AUC are not proportional to dose over certain ranges (25-100 mg/day and 25-150 mg/day), though approximately linear between 100-150 mg/day 2
- Potential for dramatically higher concentrations: At doses above 150 mg/day, significant dose dependency may lead to unexpectedly elevated plasma levels 2
- CYP2D6 metabolism: Clomipramine is metabolized by cytochrome P450 2D6; poor metabolizers (7-10% of Caucasians) have substantially higher plasma concentrations 7, 2
Dosing
OCD Treatment
- Initial dose: 25 mg/day 2
- Titration: Gradually increase over first 2 weeks to approximately 100 mg/day in divided doses 2
- Maintenance: May be further increased over several weeks to maximum of 250 mg/day 2, 3
- Response threshold: Most often associated with doses greater than 75 mg/day 3
- Maximum recommended daily dose: 250 mg 2, 3
Premature Ejaculation
- Daily dosing: 25-50 mg/day 5
- Situational dosing: 25 mg taken 4-24 hours prior to intercourse 5
- Adverse effects and beneficial effects appear dose-related 5
Pediatric Dosing (OCD)
- Safety and effectiveness established only for pediatric patients with OCD 2
- Similar dosing approach as adults, with careful titration 2
Adverse Effects
Common Adverse Effects (≥1% incidence)
Gastrointestinal: 2
- Dry mouth (most common)
- Constipation
- Nausea
- Dyspepsia
- Anorexia
Nervous System: 2
- Somnolence
- Tremor
- Dizziness
- Nervousness
- Myoclonus
Genitourinary: 2
- Changed libido
- Ejaculatory failure
- Impotence
- Micturition disorder
Other: 2
- Fatigue
- Sweating
- Increased appetite
- Weight gain
- Visual changes
Serious Adverse Effects
Seizures: 2
- Dose-related incidence: 0.48% at ≤250 mg/day; 2.1% at ≥300 mg/day 8
- Risk increases with higher doses and in CYP2D6 poor metabolizers 7
- Fatal case reported: 9-year-old CYP2D6 poor metabolizer on high-dose fluoxetine (80-100 mg/day) experienced seizures, status epilepticus, cardiac arrest, and death 7
- Potential for cardiotoxicity, especially conduction impairment
- Orthostatic hypotension
- QT prolongation risk
- ECG changes
- Risk with concomitant use of MAOIs, lithium, sumatriptan, tryptophan
- Mild cases: headache, nausea, sweating, dizziness
- Severe cases: hyperthermia, rigidity, delirium, coma
Hepatotoxicity: 2
- Elevated aminotransferase values (uncommon but potentially serious)
Withdrawal Symptoms: 2
- Jitteriness, tremor, seizures reported in neonates whose mothers took clomipramine until delivery
Discontinuation Rates
- Approximately 20% of patients discontinued treatment due to adverse events in U.S. premarketing trials 2
- Primary reasons: nervous system complaints (5.4%, mainly somnolence) and digestive complaints (1.3%, mainly vomiting/nausea) 2
Drug Interactions
Critical Interactions
MAOIs: 2
- Contraindicated due to risk of serotonin syndrome
- Sufficient time must elapse before switching between drug classes
SSRIs: 2
- All SSRIs inhibit CYP2D6 to varying degrees (fluoxetine, sertraline, paroxetine, fluvoxamine)
- Fluvoxamine also inhibits CYP1A2, another isoform involved in TCA metabolism
- When combining SSRI with clomipramine, expect increased blood levels of both drugs 1
- At least 5 weeks washout required when switching from fluoxetine to clomipramine due to fluoxetine's long half-life 2
CYP2D6 Inhibitors: 2
- Quinidine, cimetidine, many antidepressants, phenothiazines, Type 1C antiarrhythmics (propafenone, flecainide)
- May require lower doses of clomipramine when co-administered
- Monitor TCA plasma levels when initiating or discontinuing CYP2D6 inhibitors 2
Highly Protein-Bound Drugs: 2
- Warfarin, digoxin: clomipramine may increase plasma concentrations, potentially causing adverse effects
- Displacement interactions are bidirectional 2
Other Interactions: 2
- Barbiturates, phenytoin: may decrease clomipramine levels
- Clomipramine may increase phenobarbital levels
- Pharmacokinetic interactions with anticonvulsants, benzodiazepines, tricyclic antidepressants, antipsychotics, tolbutamide, antiarrhythmics, warfarin (especially in elderly) 5
Contraindications
- Concomitant MAOI use 2
- Recent myocardial infarction 2
- Hypersensitivity to clomipramine or other tricyclic antidepressants 2
Special Populations
Pregnancy
- No teratogenic effects observed in animal studies at doses up to 24 times the maximum recommended human dose 2
- Withdrawal symptoms reported in neonates whose mothers took clomipramine until delivery 2
- Use only if potential benefit justifies potential risk to fetus 2
Nursing Mothers
- Clomipramine found in human breast milk 2
- Decision required: discontinue nursing or discontinue drug, considering importance of drug to mother 2
Pediatric Use
- Safety and effectiveness established only for OCD in children and adolescents 2
- Adverse reaction profile similar to adults 2
- 196 adolescents studied: 50 were ≤13 years, 146 were 14-17 years 2
CYP2D6 Poor Metabolizers
- 7-10% of Caucasians are poor metabolizers 7, 2
- Higher plasma concentrations at usual doses (up to 8-fold increase in AUC) 2
- Increased risk of serious adverse effects including seizures and cardiac events 7
- Consider genetic testing or therapeutic drug monitoring 7
Clinical Pearls
Monitoring
- Therapeutic drug monitoring recommended when combining with CYP2D6 inhibitors or in suspected poor metabolizers 2, 10
- Target plasma concentrations not definitively established, but monitoring helps optimize therapy and avoid toxicity 10
- ECG monitoring advisable given cardiotoxicity risk 6, 9
Treatment Duration
- Initial response: Effects typically seen at 4 weeks; improvement may continue up to 18 weeks 6
- Maintenance: Long-term treatment often necessary; relapse frequently reported upon withdrawal 3, 9
Comparison to SSRIs
- While potentially more efficacious than SSRIs in some analyses, SSRIs remain first-line due to superior tolerability and safety profile 1
- Clomipramine reserved for SSRI non-responders or as augmentation strategy 1